Markets:

Overview

News

Currencies

International

Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

4.640 +0.240 (+5.45%)

Streaming Delayed Price Updated: 1:37 PM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 High-Flying Stocks We’re Skeptical Of

Today 0:32 EDT

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...

Via StockStory

1 Unprofitable Stock to Consider Right Now and 2 We Turn Down

May 22, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

Topics Energy

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 12, 2026

Myriad Genetics began 2026 with results that fell short of Wall Street’s expectations, as the company posted modest year-over-year sales growth but missed on...

Via StockStory

Topics Earnings

3 of Wall Street’s Favorite Stocks with Open Questions

May 12, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS ↗

May 05, 2026

Via Chartmill

Topics Earnings

Myriad Genetics Inc (NASDAQ:MYGN) Stock Surges 19.6% on Strong Q4 Earnings Beat ↗

February 23, 2026

Via Chartmill

MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins

May 06, 2026

Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio...

Via StockStory

Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%

May 05, 2026

Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio...

Via StockStory

Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect

May 03, 2026

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Tuesday after market close. Here’s what you need to know. Myriad Geneti...

Via StockStory

Topics Artificial Intelligence

3 Small-Cap Stocks We Think Twice About

April 24, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

1 Cash-Burning Stock to Target This Week and 2 We Question

April 13, 2026

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...

Via StockStory

Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

April 05, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

3 Healthcare Stocks with Open Questions

April 02, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Government Stocks

2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off

March 17, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

March 11, 2026

Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted...

Via StockStory

Topics Artificial Intelligence

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

March 11, 2026

Shareholders of Myriad Genetics would probably like to forget the past six months even happened. The stock dropped 31.8% and now trades at $5.24. This may ha...

Via StockStory

Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know

March 10, 2026

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha...

Via StockStory

Topics Artificial Intelligence Earnings

3 Stocks Under $10 We Keep Off Our Radar

March 10, 2026

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many ...

Via StockStory

2 Unprofitable Stocks on Our Buy List and 1 We Brush Off

March 05, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

March 03, 2026

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5.9% in the afternoon session after the company announced the launch of...

Via StockStory

Topics Earnings Economy Stocks

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key...

Via StockStory

Topics Economy Government Stocks

Why Myriad Genetics (MYGN) Stock Is Trading Up Today

February 24, 2026

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 4.9% in the morning session after the company reported better-than-expected fourth-quarter 2025 earnings that surpassed analyst...

Via StockStory

Topics Government World Trade

Myriad Genetics (MYGN) Q4 2025 Earnings Transcript ↗

February 23, 2026

Myriad Genetics (MYGN) Q4 2025 Earnings Transcript

Via The Motley Fool

What's going on in today's after hours session ↗

February 23, 2026

Via Chartmill

Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22%

February 23, 2026

Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full...

Via StockStory

iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know

February 23, 2026

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...

Via StockStory

Topics Government World Trade

3 Cash-Burning Stocks We Keep Off Our Radar

February 05, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...

Via StockStory

Topics Bankruptcy

1 Small-Cap Stock on Our Watchlist and 2 That Underwhelm

February 02, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm

January 21, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...

Via StockStory

Topics Economy Stocks

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.